Volv Global CEO Christopher Rudolf speaks at the DREAMS Neuromuscular Disease AI Webinar
Volv Global CEO Christopher Rudolf will speak at the DREAMS Neuromuscular Disease AI Webinar
Some of these diseases are rare. Others are common but easily missed, because their symptoms mirror something more familiar. Either way, patients often wait years for a diagnosis that names what is happening to them.
Volv Global works across a growing number of these conditions. Each disease page sets out the numbers behind it, the signs and symptoms most often missed, and what our research is learning about the gap to diagnosis.
A life-threatening lung condition that goes unrecognised in as many as 4 in 10 patients on the day it first appears.
A hereditary condition strongly linked to COPD and liver disease, with most people who carry it never diagnosed.
Breast cancer is a group of cancers defined by receptor status, and that status now determines more than 90% of treatment choice. Most patients are found through screening, so the opportunity lies in finding patients whose subtype, biomarker or germline testing has not kept pace with new treatment options, such as HER2-low disease, post-CDK4/6 inhibitor mutations and BRCA carriers.
A rare, inherited condition that often goes unrecognised for over a decade, as symptoms mimic more common diseases.
Friedreich ataxia is a difficult-to-diagnose inherited mitochondrial disease causing progressive ataxia, cardiomyopathy and scoliosis, with symptoms split across specialities that delay a single-gene diagnosis.
Huntington disease is a fatal inherited brain disorder causing movement, cognitive and psychiatric decline; most gene-positive carriers remain undiagnosed for years before any clinical sign appears.
MSA is a fatal, rapidly progressive neurodegenerative disease combining severe autonomic failure with parkinsonism or ataxia, difficult to diagnose because it mimics Parkinson’s disease.
A group of slow-growing but serious tumours whose vague, wide-ranging symptoms often delay diagnosis by years.
A rare muscle-wasting condition whose milder, later-onset form can take five to twelve years to diagnose.
Sjögren's Disease is a chronic autoimmune disease causing dry eyes and mouth, with sicca symptoms scattered across ophthalmology, dentistry and rheumatology so the underlying systemic cause often goes unrecognised.
Spinal muscular atrophy destroys motor neurones from birth. Three therapies now exist, yet UK adults wait 25 years between diagnosis and treatment.
TK2D is an ultra-rare, progressive mitochondrial muscle disease causing DNA depletion and respiratory failure; patients are difficult to diagnose and often go unrecognised until crisis.
ATTR-CM is a progressive infiltrative heart disease caused by misfolded transthyretin protein, routinely mistaken for common heart failure with preserved ejection fraction and left undiagnosed for years.
WHIM syndrome is an ultra-rare inherited immune disorder causing neutropenia, warts and recurrent infections, split across four specialties so it is difficult to diagnose and often missed for years.
XLH is a hereditary phosphate-wasting disorder causing rickets in children and osteomalacia in adults; most adults were never genetically confirmed and remain difficult to find in claims data.
Volv Global CEO Christopher Rudolf will speak at the DREAMS Neuromuscular Disease AI Webinar
Volv Global at the 25th Annual NEALS Meeting, presenting new research on early identification of ALS using advanced M...
Presenting new research on whether a machine learning model can flag which patients with CAP are most likely to progr...
Results for the model flagging early ARDS risk in pneumonia will be presented at ERS Congress 2026.
Volv Global at ERS Congress 2026, presenting new research in collaboration with CSL Behring: Can We Catch ARDS Before...
Volv Global applied machine learning to 24M UK primary care records, surfacing ~1,200 undiagnosed GEP-NET patients, 5...
GEP-NETs are among the most diagnostically elusive tumours in oncology. This case study shows how machine learning ap...
Machine learning applied to 3,549 confirmed Pompe disease patients – the largest machine learning study of the diseas...
New research demonstrates that machine learning can map clinician-defined endpoints to real-world claims data in Pomp...
Explore Volv Global’s ISPOR 2026 research with Sanofi on Pompe disease, based on use of machine learning-driven endpo...
In Inflammatory Bowel Disease (IBD), steroids are considered a routine treatment, but repeated steroid exposure is a ...
AI-driven insights & RWD in Rare Disease: Accelerate AATD Diagnosis and identify undiagnosed AATD patients earlie...